Provention Bio, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $12.9M | $1.4M | — | — | — | — |
| Operating income | −$128.2M | −$115.6M | −$99.7M | −$44.4M | −$26.8M | −$9.1M |
| Net income | −$113.6M | −$114.4M | −$98.6M | −$43.3M | −$26.5M | −$9.1M |
| Total assets | $236.9M | $135.6M | $128.5M | $86.0M | $61.5M | $22.4M |
| Total liabilities | $115.0M | $24.9M | $17.4M | $3.8M | $1.9M | $2.3M |
| Equity | $121.8M | $110.7M | $111.1M | $82.2M | $59.7M | −$6.0M |
| EPS (diluted) | $-1.52 | $-1.81 | $-1.88 | — | — | — |
| Shares out. | 63.4M | 63.4M | 47.7M | 37.4M | 37.4M | 10.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −993.9%
- Net margin
- −880.7%
- Return on equity
- −93.2%
- Return on assets
- −47.9%
- Return on capital (ROCE)
- −87.5%
- Liabilities / assets
- 48.6%
- Debt / equity
- 0.94×
- Book value / share
- $1.92
- Revenue growth (YoY)
- 824.4%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -5.77distress
- Accruals / assets
- −16.1%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 27, 2023
- Entered a material agreement · Director / officer change · Amended charter or bylaws · Other material eventMar 13, 2023
- Unregistered equity sale · Regulation FD disclosureFeb 13, 2023
- Entered a material agreement · New financial obligation · Unregistered equity saleFeb 2, 2023
- Director / officer change · Regulation FD disclosureJan 5, 2023
- Other material eventDec 6, 2022
- Regulation FD disclosure · Other material eventNov 18, 2022
- Results of operationsNov 3, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.